Results 1 to 10 of about 2,451,718 (370)

Prescribers’ satisfaction with delivering medications for opioid use disorder [PDF]

Substance Abuse Treatment, Prevention, and Policy, 2021
Background Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering ...
Hannah K. Knudsen, Randy Brown, Nora Jacobson, Julie Horst, Jee-Seon Kim, Hanna Kim, Lynn M. Madden, Eric Haram, Todd Molfenter   +8 more
doaj   +9 more sources

Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder [PDF]

Addiction Science & Clinical Practice
Background Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low.
Nicholas C. Cardamone, Rebecca E. Stewart, Kyle M. Kampman, Steven C. Marcus   +3 more
doaj   +4 more sources

Concurrent opioid and alcohol withdrawal management [PDF]

Mental Health Clinician, 2023
Concurrent alcohol and opioid withdrawal syndrome is a common and challenging clinical scenario with little published evidence or guidance to inform pharmacotherapy strategies.
Michelle Colvard, PharmD, BCPP
doaj   +1 more source

Medication Treatment of Opioid Use Disorder [PDF]

Biological Psychiatry, 2020
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist).
James Bell, John Strang
openaire   +5 more sources

Medications Development for Treatment of Opioid Use Disorder [PDF]

Cold Spring Harbor Perspectives in Medicine, 2020
This review describes methods for preclinical evaluation of candidate medications to treat opioid use disorder (OUD). The review is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effectiveness, (2) procedures that assess choice between opioid and nondrug reinforcers ...
E. Andrew Townsend, S. Stevens Negus, Matthew L. Banks   +2 more
openaire   +2 more sources

Attending a Biopsychosocially Focused Buprenorphine Training Improves Clinician Attitudes

Frontiers in Psychiatry, 2021
Objective: Substance use disorders remain highly stigmatized. Access to medications for opioid use disorder is poor. There are many barriers to expanding access including stigma and lack of medical education about substance use disorders. We enriched the
Holly Ann Russell, Brian Smith, Mechelle Sanders, Elizabeth Loomis   +3 more
doaj   +1 more source

Medication-Assisted Treatment for Opioid-Use Disorder [PDF]

Mayo Clinic Proceedings, 2019
The United States is in the midst of a national opioid epidemic. Physicians are encouraged both to prevent and treat opioid-use disorders (OUDs). Although there are 3 Food and Drug Administration-approved medications to treat OUD (methadone, buprenorphine, and naltrexone) and there is ample evidence of their efficacy, they are not used as often as they
Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans, Mark S. Gold   +3 more
openaire   +6 more sources

Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study

Addiction Science & Clinical Practice, 2022
Background Residential treatment is a common approach for treating opioid use disorder (OUD), however, few studies have directly compared it to outpatient treatment.
Daniel M. Hartung, Sheila Markwardt, Kirbee Johnston, Jonah Geddes, Robin Baker, Gillian Leichtling, Christi Hildebran, Brian Chan, Ryan R. Cook, Dennis McCarty, Udi Ghitza, P. Todd Korthuis   +11 more
doaj   +1 more source

A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder

Frontiers in Psychiatry, 2023
Stigma toward people taking medication for opioid use disorder (MOUD) is prevalent, harmful to the health and well-being of this population, and impedes MOUD treatment resource provision, help-seeking, and engagement in care.
Timothy D. Becker, Timothy D. Becker, Evan L. Eschliman, Ashish P. Thakrar, Lawrence H. Yang, Lawrence H. Yang   +5 more
doaj   +1 more source

Discordance in Addressing Opioid Crisis in Rural Communities: Patient and Provider Perspectives

Pharmacy, 2022
Providing patient-centered care to manage chronic pain and opioid use disorder (OUD) is associated with improved health outcomes. However, adopting a holistic approach to providing care is often challenging in rural communities.
Bonyan Qudah, Martha A. Maurer, David A. Mott, Michelle A. Chui   +3 more
doaj   +1 more source